RMX Biopharma Co., Ltd (Headquarter in Hongzhou, China, CEO: RuiPing Dong) (RMX), initiated a clinical study with grapiprant in the People's Republic of China (China) on September 20, 2018. RMX licensed our licensee AskAt Inc. for pain indications in China on January 1, 2016. This is the first clinical trial in China. Grapiprant has previously demonstrated efficacy, safety, and tolerability in Phase 2 clinical trials in the United States for osteoarthritis-associated pain. Under the license agreement between RaQualia and AskAt, RaQualia is eligible to receive development milestones and royalties on sales of the product.